Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial by van Jaarsveld, C.H.M. et al.
Aggressive treatment in early rheumatoid arthritis:
a randomised controlled trial
CHMv a nJ a a r s v eld, JWGJ acobs, M J van der Veen, A A M Blaauw, A A Kruize,
D M Hofman, HLMB r u s ,GAv a nAlbada-Kuipers, A H M Heurkens, E J ter Borg,
H C M Haanen, C van Booma-Frankfort, Y Schenk, J W J Bijlsma on behalf of the
Rheumatic Research Foundation Utrecht, The Netherlands
Abstract
Objectives—To compare three therapeutic
strategies using slow acting antirheumatic
drugs (SAARDs) in early rheumatoid
arthritis (RA), for their disease modifying
properties, toxicity, and lag time until
treatment eVect.
Methods—Patients with recent onset RA
from six hospitals were randomly assigned
to immediate initiation of one of three
treatment strategies: (I) a “mild SAARD
with a long lag time” (hydroxychloro-
quine, if necessary replaced by au-
ranoﬁn); (II) a “potent SAARD with a
long lag time” (intramuscular gold, if nec-
essary replaced by D-penicillamine); (III)
a “potent SAARD with a short lag time”
(methotrexate, if necessary replaced by
sulfasalazine). Comparisons included two
years of follow up.
Results—All SAARD strategies reduced
mean disease activity. A greater percent-
age of patients improved clinically with
strategies II and III than with strategy I:
percentages of patients improved on joint
score with strategies II and III (79% and
82%, respectively), which was statistically
diVerent from strategy I (66%). The same
was true for remission percentages: 31%
and 24% v 16%, respectively). Longitudi-
nal analysis showed signiﬁcantly less dis-
ability with strategy III, and a lower
erythrocyte sedimentation rate with strat-
egy II than with strategy I. In addition,
radiological damage after one and two
years, was signiﬁcantly lower in strategies
II and III (at two years median scores were
11 and 10 v 14 in strategy I, p<0.05). Toxic-
ity was increased in strategy II compared
with the other strategies.
Conclusion—Strategy III, comprising
methotrexate or sulfasalazine, produced
the best results weighing eVectiveness and
toxicity. Strategy I (hydroxychloroquine
or auranoﬁn) was slightly less eVective,
and strategy II (intramuscular gold or
D-penicillamine) was associated with in-
creased toxicity.
(Ann Rheum Dis 2000;59:468–477)
Rheumatoid arthritis (RA) is a chronic disease
characterised by symmetrical polyarthritis.
Pharmacotherapy consists of non-steroidal
anti-inﬂammatory drugs (NSAIDs), slow act-
ing antirheumatic drugs (SAARDs), and corti-
costeroids. Traditionally, RA treatment in-
volved conservative management with NSAIDs
given for long periods.If insuYciently eVective,
NSAIDs were supplemented with an SAARD.
SAARDs are believed to inﬂuence the outcome
of RA positively in contrast with NSAIDs,
which are only symptom relieving. In the past
decade the therapeutic management has
changed towards more aggressive manage-
ment.In line with other reports,
12our previous
results from the Utrecht Rheumatoid Arthritis
Cohort show that after one year early interven-
tion with SAARDs is more eVective than treat-
ment with NSAIDs only.
3
The SAARDs that are used to treat RA dif-
fer in their disease modifying properties, toxic-
ity, and lag time until treatment eVect. In gen-
eral, the more potent SAARDs are also
believed to be the more toxic. Antimalarial
drugs (hydroxychloroquine) are thought to be
the least eVective and less toxic than the other
SAARDs. The maximum beneﬁcial eVects of
hydroxychloroquine are not seen until after
three to six months.
4 Oral gold (auranoﬁn) has
similar characteristics.
56 Intramuscular gold
and D-penicillamine are more potent but also
more toxic,
7–9 the lag time between the start
and treatment eVect is relatively long (more
than three months). Many rheumatologists
regard methotrexate as a potent and toxic drug,
and therefore only prescribe methotrexate if
other SAARDs are insuYciently eVective. The
eVect of methotrexate has been shown to start
within four to six weeks.
10 Sulfasalazine is also
regarded as an SAARD with a relatively short
lag time.
41 1
Thus the most commonly used SAARDs can
be classiﬁed into three groups: mild with a
relatively long lag time (hydroxychloroquine,
auranoﬁn), more potent with an expected long
lag time (intramuscular gold, D-penicillamine),
and potent with a relatively short lag time
(methotrexate, sulfasalazine). It is not clear
whether one of these SAARD groups is
superior in the treatment of early RA. In this
study the eVectiveness, lag time, and side
eVects of the three diVerent strategies accord-
ing to the three groups described above are
compared after one and two years of follow up.
Methods
PATIENTS
The study was designed as a prospective open
label randomised controlled trial. Since 1990
all patients with recent onset RA (according to
the American Rheumatism Association crit-
eria),
12 from all (six) rheumatological centres in
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12 January 2000the Utrecht region of the Netherlands, were
asked to participate in a randomised prospec-
tive clinical trial. Disease duration had to be
less than one year; most patients were enrolled
shortly after the diagnosis was established.One
university hospital and ﬁve general hospitals
are included in this multicentre trial,covering a
population of approximately one million peo-
ple. The following exclusion criteria were
applied: age <17 years; comorbid conditions
that might interfere with one of the therapeutic
strategies (such as malignancy,cardiac,respira-
tory, hepatic, and renal insuYciency); previous
or current treatment with SAARDs, cortico-
steroids, cytotoxic or immunosuppressive
drugs; possible pregnancy or breast feeding;
psychiatric or mental disturbances that make
adherence to study protocol unlikely. All
patients signed informed consent; the ethical
committees of all participating hospitals ap-
proved the study design. Baseline characteris-
tics of patients eligible for the study but object-
ing to randomisation were compared with
those of randomised patients to see if any
selection bias had occurred.
TREATMENT
Patients entering the study were randomly
assigned to one of three therapeutic strategies:
Strategy I: Treatment was started with
hydroxychloroquine (400 mg daily): a mild
SAARD with an expected long lag time until
treatment eVect; if necessary replaced by
auranoﬁn (6–9 mg daily), an SAARD with the
same characteristics.
Table 1 Baseline characteristics*
Variable,unit (range)
Strategy I
(n=107)
Strategy II
(n=101)
Strategy III
(n=105)
Dropouts
(n=31)
Patients who were
not randomly
assigned (n=52)
Female sex, % 69 65 64 52 81
Rheumatoid factor positive, % 67 56 65 55 69
Age, years
Mean 56 55 57 67† 55
10–90 Centiles 37–74 35–73 37–73 38–79 30–73
Primary end points
Disability score (0–3)
Mean 1.4 1.3 1.3 1.5 1.0†
10–90 Centiles 0.5–2.5 0.1–2.4 0.3–2.4 0.4–2.6 0.1–2.1
Pain score, mm (0–100)
Mean 46 43 44 43 31†
10–90 Centiles 9–86 3–82 9–92 1–96 1–72
Joint score (0–534)
Mean 141 147 142 152 110
10–90 Centiles 35–306 38–280 44–279 47–357 20–226
ESR, mm/1st h (0–140)
Mean 42 41 43 41 39
10–90 Centiles 11–86 9–88 14–88 14–87 8–92
Radiological damage (0–448)
Median 2 2 2 2 2
10–90 Centiles 0–12 0–11 0–13 0–6 0–10
Secondary end points
Wellbeing, mm (0–100)
Mean 49 50 49 48 39
10–90 Centiles 6–90 6–82 12–92 12–92 2–80
Grip strength, kPa (0–120)
Mean 30 33 31 24 35
10–90 Centiles 4–58 6–67 5–58 1–43 9–59
Haemoglobin, mmol/l
Mean 7.8 8.0 8.0 8.1 7.8
10–90 Centiles 6.5–9.0 6.9–9.1 6.8–9.0 7.1–9.2 6.7–9.0
Morning stiVness, min (0–720)
Median 60 60 60 60 30
10–90 Centiles 10–360 5–180 3–360 1–288 0–162
C reactive protein, mg/l
Median 26 20 16 18 18
10–90 Centiles 0–94 0–85 0–72 0–79 0–70
Platelet count ´ 10
9/l
Median 321 332 317 330 317
10–90 Centiles 215–503 220–482 219–483 218–436 243–522
*Higher values indicate more active disease, with the exception of values for grip strength and haemoglobin.
Mean was presented for normal distribution of the variables, and median for a skew distribution. Presented ranges are theoretical
ranges.
†Dropouts had a signiﬁcantly higher age than all other groups (analysis of variance (ANOVA), p = 0.002).
Patients who were not randomly assigned diVered signiﬁcantly from all other groups: less disability (ANOVA, p = 0.05) and lower
pain score (ANOVA, p = 0.04).
Table 2 Number of patients whose assigned strategies were discontinued and reasons for
discontinuation
Strategy*
Period
(years)
Patients who
discontinued
strategy
No (%)
Reasons for discontinuation†
Adverse
reaction IneVectiveness
Adverse reaction
and ineVectiveness Other
I 0–1 12 (11) 0 12 0 0
1–2 17 (16) 5 10 2 0
0–2 29 (27) 5 22 2 0
II 0–1 4 (4) 1 2 0 1
1–2 26 (26) 15 9 1 1
0–2 30 (30) 16 11 1 2
III 0–1 11 (10) 4 4 1 2
1–2 10 (10) 3 7 0 0
0–2 21 (20) 7 11 1 2
*Strategy I: mild slow acting antirheumatic drug (SAARD) with an expected long lag time:
hydroxychloroquine or auranoﬁn.
Strategy II:potent SAARD with an expected long lag time:intramuscular gold or D-penicillamine.
Strategy III: potent SAARD with a relatively short lag time: methotrexate or sulfasalazine.
Discontinuation rates after one and two years were not statistically signiﬁcantly diVerent between
the three strategies.
†Results are shown as number of patients.
SAARD strategies in early RA 469Strategy II: Treatment with intramuscular
gold (aurothioglucose, IM gold, 50 mg
weekly): a more potent and toxic SAARD with
an expected long lag time;if necessary replaced
by D-penicillamine (500–750 mg daily), an
SAARD with the same characteristics.
Strategy III: Treatment with oral methotrex-
ate (7.5–15 mg weekly): a relatively fast acting,
potent SAARD; if necessary replaced by
sulfasalazine (2–3 g daily),an SAARD with the
same characteristics.
Randomisation was performed by an inde-
pendent person, in blocks of 100 patients per
hospital. The initial SAARD (hydroxychloro-
quine, IM gold, or methotrexate) was contin-
ued unless adverse reactions or ineVectiveness
made discontinuation inevitable in the view of
the attending doctor, in which case the second
SAARD of that particular strategy was given.
Treatment with an SAARD other than the ini-
tial or the second SAARD was regarded as dis-
continuation of the therapeutic strategy. Pa-
tients who could stop taking drugs owing to
remission were not considered as having
discontinued the strategy.
Use of NSAIDs and analgesics was allowed
in all strategies. Oral corticosteroids and intra-
articular injections with corticosteroids were
avoided. Criteria for dose adjustment due to
adverse reactions were described in detail in
the study protocol. After one year of treatment
responses were assessed for each patient.When
improvement of at least 50% from the start of
the drug was seen in at least three of four vari-
ables (pain, joint score, morning stiVness,
erythrocyte sedimentation rate (ESR)) the
SAARD was continued. The initial SAARD
was stopped in patients who did not meet these
criteria, and treatment with the second
SAARD from the strategy was started. If a
patient fulﬁlled the remission criteria at three
subsequent visits (six months), the dosage of
the SAARD was reduced to half—that is,
halved dosages of hydroxychloroquine, au-
ranoﬁn, D-penicillamine, sulfasalazine were
continued daily and halved dosages of IM gold,
methotrexate were continued weekly. Patients
were considered to be in remission when the
duration of morning stiVness was <15
minutes, the pain score was <10 mm, the
Table 3 Changes from baseline in primary end points
Primary end points†
Change from baseline* DiVerence
between
strategies Strategy I (n=107) Strategy II (n=101) Strategy III (n=105)
1 year
Disability score −0.3 (−0.5 to −0.2) −0.4 (−0.5 to −0.2) −0.4 (−0.5 to −0.3)
Pain score, mm −21 (−27 to −15) −18 (−25 to −12) −24 (−28 to −18)
Joint score −74 (−99 to −49) −93 (−118 to −67) −95 (−113 to −78)
ESR, mm/1st h −16 (−20 to −12) −18 (−24 to −12) −20 (−25 to −16)
Radiological damage ‡
Median +6 +3 +2
10–90 Centiles 0–25 0–15 0–14
2 years
Disability score −0.3 (−0.5 to −0.2) −0.4 (−0.6 to −0.2) −0.3 (−0.4 to −0.2)
Pain score, mm −22 (−27 to −16) −25 (−31 to −19) −21 (−27 to −16)
Joint score −89 (−111 to −67) −104 (−128 to −80) −86 (−106 to −66)
ESR, mm/1st h −19 (−24 to −14) −21 (−27 to −16) −20 (−24 to −15)
Radiological damage ‡
Median +12 +9 +8
10–90 Centiles 0–48 0–28 0–37
*Values are the mean change from baseline and 95% CI for the mean. For radiological damage values are median change and the
10–90 centiles. Negative values indicate improvement for all end points.
†Ranges for end point measures are as follows: disability score, 0 to 3; pain score, 0 to 100 mm; joint score, 0 to 534; erythrocyte
sedimentation rate, 1 to 140 mm/1st h; radiological damage score, 0 to 448.
‡DiVerences between strategies I and II, and between I and III were signiﬁcant (p<0.05), but not between strategies II and III
(Mann-Whitney U test).
Table 4 Changes from baseline in secondary end points
Secondary end points†
Change from baseline* DiVerence
between
strategies Strategy I (n=107) Strategy II (n=101) Strategy III (n=105)
1 year
Wellbeing score, mm −17 (−23 to −10) −21 (−28 to −14) −22 (−27 to −16)
Grip strength, kPa +9 (+6 to +12) +9 (+5 to +13) +14 (+10 to +18) ‡
Haemoglobin, mmol/l +0.2 (+0.01 to +0.4) +0.3 (+0.2 to +0.5) +0.3 (+0.2 to +0.4)
Morning stiVness, min median (10–90 centiles) −30 (−270 to +60) −45 (−178 to +27) −30 (−233 to +23)
C reactive protein, mg/l median (10–90 centiles) −15 (−66 to +13) −9 (−94 to +14) −12 (−54 to +5)
Platelet count ´ 10
9/l median (10–90 centiles) −33 (−134 to 29) −50 (−166 to +40) −45 (−177 to +17)
2 years
Wellbeing score, mm −17 (−23 to −11) −24 (−30 to −17) −18 (−24 to −12)
Grip strength, kPa +12 (+8 to +15) +13 (+8 to +17) +15 (+11 to +20)
Haemoglobin, mmol/l +0.2 (+0.04 to +0.4) +0.4 (+0.2 to +0.5) +0.4 (+0.2 to +0.5)
Morning stiVness, min median (10–90 centiles) −45 (−309 to +36) −45 (−150 to +30) −30 (−216 to +45)
C reactive protein, mg/l median (10–90 centiles) −18 (−74 to +5) −11 (−95 to +6) −5 (−55 to +5)
Platelet count ´ 10
9/l median (10–90 centiles) −42 (−171 to +29) −63 (−206 to +30) −50 (−173 to +19)
*Values are the mean change from baseline and 95% CI for the mean, or the median change and 10–90 centiles, where appropriate.
†Ranges for end points are: wellbeing score 0 to 100 mm; duration of morning stiVness 0 to 720 minutes. Negative values indicate improvement for all end points,
except for grip strength and haemoglobin concentration.
‡DiVerences between strategies were not statistically signiﬁcant, except for grip strength at one year: diVerence in change in grip strength between strategies I and III
was statistically signiﬁcant : mean diVerence is 5 and 95% CI of the diVerence is 0.2 to 10.0, but not between strategies II and III: mean diVerence is 5 and 95% CI
of the diVerence is −0.2 to 10.0.
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was < 30 mm/1st h.
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PRIMARY END POINTS
Primary end points were pain, functional
disability, joint score, ESR, and radiological
damage.
14 Assessments were performed at the
start of the trial and repeated every three
months, except for radiological damage, which
was assessed annually. The same doctor or
research nurse assessed clinical variables on
each occasion. Functional disability was as-
sessed with a validated Dutch version of the
Health Assessment Questionnaire, range 0–3:
zero representing the best (no problems) and
three the worst score.
15 16 Pain was measured
separately for night and morning on two hori-
zontal visual analogue scales of 100 mm; the
mean of the scores was calculated. The joint
score according to Thompson assessed the
simultaneous presence of joint tenderness and
swelling in a selection of joints weighted for
joint size; range 0–534.
17 18 Joints that received
an injection within two months before an
evaluation were not included in the score. ESR
in mm after one hour was measured by the
Westergren method. A modiﬁed method of
Sharp was used to score radiological
abnormalities.
19 20 Erosions and joint space
narrowing in hand and foot joints were scored
and added to obtain a total score (range
0–448). Two investigators, unaware of the
therapeutic strategy, evaluated all radiographs.
Investigators evaluated the three consecutive
radiographs for each patient in line and were
aware of the sequence of radiographs. The
scores of the ﬁrst investigator were used in the
analyses; the scores of the second were used to
validate the scores of the ﬁrst. DiVerences in
total scores in individual cases of 25% or more
were discussed until agreement was reached.
SECONDARY END POINTS
Additional end points were duration of morn-
ing stiVness (maximum 720 min); general
wellbeing (horizontal visual analogue scale of
100 mm); grip strength (mean of three
measurements of each hand with a Martin
vigorimeter in kPa); serum concentration of C
reactive protein (mg/l), haemoglobin concen-
tration (mmol/l), and platelet count (´10
9/l).
Rheumatoid factor status was considered posi-
tive if the qualitative Latex ﬁxation test at a
dilution of 1:1 was positive or the Rose-Waaler
test was positive (that is, titre >40 IU/ml), or
both. These cut oV points result in a positive
test in fewer than 5% of the general population.
STATISTICAL ANALYSIS
The intention to treat principle was applied; in
addition on-protocol or complier analyses were
performed including only those patients who
continued to be treated according to the
randomised strategy. DiVerences in mean
changes from baseline for all end points
between the strategies were tested for statistical
signiﬁcance with analysis of variance (ANOVA)
or the Kruskal-Wallis test, where appropriate.
Radiological damage, morning stiVness, C
reactive protein, and platelet count showed a
Figure 1 Mean disability score in 150 patients with available data on disability for all
nine measurements in each therapeutic strategy.There was a signiﬁcant diVerence between
strategies I and III (p = 0.04),and a signiﬁcant decrease in disability over time in each
strategy (analysis of variance for repeated measurements).
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Figure 2 Mean pain score in 243 patients with available data on pain for all nine
measurements in each therapeutic strategy.Signiﬁcant decrease in pain score over time in
each strategy,no signiﬁcant diVerence between the strategies (p = 0.23) (analysis of
variance for repeated measurements).
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Figure 3 Mean joint score in 247 patients with available data on joint score for all nine
measurements in each therapeutic strategy.Signiﬁcant decrease in joint score over time in
each strategy,no signiﬁcant diVerence between the strategies (p = 0.30) (analysis of
variance for repeated measurements).
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SAARD strategies in early RA 471skewed distribution. Therefore, median scores
were presented for these variables. ANOVA for
repeated measurements was used to study dif-
ferences between the strategies using all the
nine three-monthly measurements in analysis.
Both the “between-subject” or strategy eVects
and the “within-subject” or longitudinal time/
overall treatment eVects were tested. ANOVA
for repeated measurements required variables
to show a normal distribution.
Clinically relevant improvement in a single
primary end point for individual patients was
deﬁned as an improvement of 33% or more
compared with baseline.
21 Patients were con-
sidered to have a clinical response when they
improved by 20% or more compared with
baseline on at least three of four primary end
points (radiological damage excluded).
22 23 Dif-
ferences between the strategies were tested for
signiﬁcance with the ÷
2 test. The deﬁnition of
remission by Scott et al was used,as mentioned
earlier.
13
No adjustments were made for multiple
comparisons.
24 Power calculations for func-
tional disability as one of the primary end
points indicated group sizes of 100 to be suY-
cient for detecting 20% diVerence between
groups at á = 0.05 and 1−â = 0.80. Statistical
analyses were performed with the SPSS for
Windows statistical package, version 6.1.
25
Toxicity was studied in each strategy. As it is
notoriously diYcult to relate an adverse event
to speciﬁc drug treatment, all possible adverse
events are included in the analysis.
26 26a For
eVectiveness analysis the intention to treat
principle was followed. The same applied for
toxicity analysis. As a consequence, all adverse
events, even if patients discontinued the
assigned treatment strategy, were included in
this analysis. Most patients (99%) also took
NSAIDs; therefore, the reported events might
also be the result of NSAID use.However,both
the rate of events unrelated to antirheumatic
drug treatment and NSAID related toxicity are
expected to be equally distributed across the
three strategies, and consequently not consid-
ered to bias the results.
Results
PATIENT CHARACTERISTICS
In April 1998 313 patients had been ran-
domised and had completed at least two years
of follow up. Data on 31 randomised patients
who were lost to follow up (dropouts) and on
52 patients who did not agree to be randomised
were not included in analyses, but baseline
characteristics were compared with those of the
other groups. Eleven patients (9%) in strat-
egy I,12 (11%) in strategy II,and eight (7%) in
strategy III were lost to follow up, after a mean
period of 7.5 months, which was not signiﬁ-
cantly diVerent between the strategies. Nine of
these 31 dropouts died of causes unrelated to
RA or its treatment (cardiac (six patients), res-
piratory insuYciency (one), malignancy (one),
sepsis (one)); four patients were excluded
because of other serious disease processes
(coronary heart disease, malignancy, lung
disease, immobility due to car accident); in
three cases the diagnosis of RA turned out to
be incorrect (systemic lupus erythematosus
(two), no chronic rheumatic disease (one));
one patient moved out of the study region; 14
patients refused to be treated following the
protocol despite initial consent (two from
strategy I, six from II, and six from III).
Table 1 shows baseline characteristics of all
the patients. The male/female ratio is typical
for an RA population. Mean age was rather
high for patients with recent onset RA, but in
line with recent epidemiological data in the
Netherlands.
27 Disease duration of all patients
was less than one year. Baseline disease status
for the randomised groups was comparable and
indicated a relatively active disease. Baseline
characteristics of the 31 patients lost to follow
up were in general comparable with those of
the therapeutic groups, except that these
patients were older. Death was one of the main
reasons for dropout, which might explain the
higher age. The 52 patients who did not agree
to be randomised had slightly better baseline
values (table 1).
Figure 4 Mean ESR score in 237 patients with available data on ESR for all nine
measurements,in each therapeutic strategy.Signiﬁcant diVerence between strategies I and II
(p = 0.01),and signiﬁcant decrease in ESR over time in each strategy (analysis of
variance for repeated measurements).
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Figure 5 Radiological progression in the three strategies.
Signiﬁcant increase over time in each strategy with
signiﬁcant interaction between overall time-treatment eVect
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than in strategy II (p = 0.03) and strategy III (p = 0.01).
No signiﬁcant diVerence between the three strategies (p =
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Discontinuation of the strategy implies treat-
ment with an SAARD other than the ﬁrst or
the second assigned SAARD. In the ﬁrst year
27 patients (9%) discontinued the randomised
strategy, and during the second year 53 (17%),
giving a total of 80 patients (26%) in two years
(table 2). Discontinuation rates did not diVer
statistically signiﬁcantly between the three
strategies. However, strategies I and II showed
slightly higher rates (27%, 30%) than strategy
III (20%).The main reason for discontinuation
was insuYcient eVectiveness in strategies I and
III and adverse reactions in strategy II.
Additional reasons were refusal of gold injec-
tions, refusal to take oral drugs, and refusal of
further treatment with any SAARD. In total,
86% of the patients at one year and 47% at two
years were still treated with the initial ran-
domised SAARD (hydroxychloroquine, IM
gold, or methotrexate). In strategy III the
maximum weekly dose of methotrexate was 7.5
mg in 51% of the patients, 10–15 mg in 43%,
and in 6% the study protocol was violated and
the dose was increased to 17.5–25 mg. Folic
acid (0.5 mg six days a week; not on the day of
methotrexate intake) was used by 33% of
patients. Folic acid was used more in patients
receiving higher doses of methotrexate: 45% of
patients using 10 mg/week methotrexate, or
higher doses, compared with 21% of patients
receiving methotrexate 7.5 mg/weekly.
CORTICOSTEROIDS
Restricted use of oral corticosteroids as adju-
vant treatment appeared to be unavoidable in
comparable percentages of patients in each of
the three strategies: 8% during the ﬁrst year
and 12% during both years. Intra-articular
injections were given at least once to 28% of
the patients during the ﬁrst year and to 44%
during both years. No signiﬁcant diVerence in
this respect between the three strategies was
found.
EFFECTIVENESS
Changes from baseline
Changes from baseline were signiﬁcant for all
primary end points in each strategy, indicated
by the 95% conﬁdence intervals of the mean
changes (table 3). Improvement seemed
slightly less in strategy I than in the other strat-
egies. However, no signiﬁcant diVerences in
change scores were observed between the three
strategies, except for radiological damage.
Although radiological progression was rather
small, median scores after one and two years
were signiﬁcantly worse for strategy I than for
strategies II or III. Complier analyses also
showed no signiﬁcant diVerences between the
three strategies, except for radiological damage
at one year, which was again high in strategy I
(data not shown).All secondary end points also
improved signiﬁcantly from baseline in each
strategy. DiVerences between the strategies
were small and statistically not signiﬁcant,
except for improvement in grip strength after
the ﬁrst year which was signiﬁcantly less in
strategy I than in III (table 4).
Longitudinal trends
Figures 1 to 5 show longitudinal trends in the
primary end points. Analysis for repeated
measurements included only those subjects
with complete data at all measurements during
the two years: disability (150 patients), pain
score (243), joint score (247), ESR (237), and
radiological damage (312).Disability over time
was favourable in strategy III compared with I
(ﬁg 1, p = 0.04). There was no signiﬁcant dif-
ference between the three strategies for pain
(ﬁg 2) and joint scores (ﬁg 3). The ESR over
time was signiﬁcantly higher in strategy I than
in II (ﬁg 4, p = 0.01). Results showed
signiﬁcant decreases in disability, pain, joint
score, and ESR over time in all three strategies.
Figure 5 shows the radiological progression.
Owing to the skewed distribution of radiologi-
cal damage, median scores are presented
instead of means. Square root transformed
data,which showed a normal distribution,were
used in repeated measurement analysis. A sig-
niﬁcant increase in the radiological damage
score over time was seen in each strategy with
Figure 6 Percentage of patients in remission at each measurement in time.Remission is
deﬁned as morning stiVness £15 min,pain score £10 mm,joint score £10,and ESR £30
mm/ 1st h.
50
40
0
24
Follow up in months
%
 
P
a
t
i
e
n
t
s
 
i
n
 
r
e
m
i
s
s
i
o
n
0 21
10
20
30
3 6 9 12 15 18
Strategy
I (n = 107)
II (n = 101)
III (n = 105)
Table 5 Patients with clinically relevant improvement*,clinical response†,and remission‡
after one and two years
No (%) patients
DiVerence between strategies
p value ÷
2 test Strategy I Strategy II Strategy III
1 year§
Disability 39 (39) 46 (52) 51 (53) NS
Pain score 70 (67) 63 (64) 75 (72) NS
Joint score 71 (66) 80 (79) 86 (82) I v II: p=0.04; I v III: p=0.01
ESR 60 (56) 64 (63) 71 (68) NS
Clinical response 58 (56) 61 (64) 72 (71) NS
Remission 17 (16) 31 (31) 25 (24) I v II: p=0.01; III v I /II: NS
2 years§
Disability 40 (41) 39 (47) 45 (47) NS
Pain score 67 (64) 71 (73) 65 (63) NS
Joint score 80 (75) 78 (78) 80 (76) NS
ESR 68 (64) 67 (67) 69 (66) NS
Clinical response 63 (61) 68 (71) 64 (63) NS
Remission 20 (19) 29 (29) 25 (24) NS
*Clinically relevant improvement is >33% improvement after one and two years respectively from
baseline.
†Clinical response is >20% improvement on three or four end points.
‡Remission: morning stiVness £15 minutes, pain score £10 mm, joint score £1, and ESR £30
mm/1st h at respectively one or two years.
§At year 1 data were missing for improvement on disability (27 patients), pain (7), ESR (1), clini-
cal response (11); at year 2 data were missing for improvement on disability (37), pain (8), joint
score (1), ESR (1), clinical response (13), and remission (2).
NS = not signiﬁcantly diVerent.
SAARD strategies in early RA 473signiﬁcant interaction between longitudinal
treatment eVect and strategy eVect, showing a
faster increase in strategy I than in strategies II
(p = 0.03) or III (p = 0.01). Progression in
strategies II and III was comparable (p = 0.67).
Lag time until treatment eVect
The lag time until treatment eVect was
deduced from the slopes of the lines during the
ﬁrst months. Figures 1, 2, and 3 show no clear
diVerences in lag time between the three strat-
egies, whereas the change in ESR occurred
faster in strategies II and III than in I (ﬁg 4).
During the ﬁrst months the slope was steeper
in strategies II and III, and levelled oV after
about three months, whereas the slope in strat-
egy I was less steep and levelled oV after about
nine months. These numerical diVerences did
not reach statistical signiﬁcance.
Clinical improvement
Table 5 shows the percentage of patients
exhibiting clinical improvement. At one year
the percentage of patients whose joint score
had improved was 79 in strategy II and 82 in
III, which is better than in strategy I (66%) (p
= 0.02). Remission rates at one year were also
higher in strategies II (31%) and III (24%)
than in strategy I (16%, p = 0.04), but no obvi-
ous diVerences were seen at two years.
Complier analysis showed higher clinical im-
provement and remission rates in strategy III at
one year compared with strategies I or II (not
statistically signiﬁcant). At year two, clinical
response rate was high in strategy II (80%)
compared with strategies I (61%) or III (63%)
(p=0.03) (data not shown). Figure 6 shows the
percentage of patients fulﬁlling remission crite-
ria at a single measurement (intention to treat
Table 6 Clinical symptoms and laboratory abnormalities in each treatment strategy
Strategy I Strategy II Strategy III
Gastrointestinal (subjective)
Nausea, vomiting, dyspepsia, epigastric pain, indigestion 35 21 39
Diarrhoea 17 7 5
Dysgeusia — 4 1
Gastrointestinal (objective)
Gastric ulcer 1 1 1
Gastritis — — 2
Gastrointestinal bleeding — — 1
Colitis 1 — 1
Colorectal surgery 1 — —
Mucocutaneous
Rash 17 47 10
Stomatitis, mouth ulcers 2 12 4
Alopecia 1 3 7
Photosensitivity 1 — —
Central nervous system
Headache, dizziness, tinnitus, mood alterations 9 7 9
Concentration disturbances 5 — 1
Renal
Proteinuria (>0.1 g/l in 24 h) 2 11 2
Raised serum creatinine (>120 µmol/l) 7 8 9
Oedema (pretibial) 2 3 3
Haematuria (macroscopic observation) — 1 2
Foul odour urine — 1 1
Hepatotoxicity
Raised transaminases or ãGT* (ALAT*>90 U/l, ãGT>100 U/l) 7 9 23
Haematological
Anaemia (Hb <6.5 mmol/l) 21 12 9
Leucopenia (<3.5 ´ 10
9/l) — 9 3
Thrombocytopenia (<150 ´ 10
9/l) 3 10 6
Eosinophilia (>0.5 ´ 10
9/l) — 2 —
Pancytopenia — 1 —
Leucopenia and thrombocytopenia — 2 —
Respiratory system
Persistent cough 1 3 3
Dyspnoea 1 2 1
Pneumonitis — 1 1
Pulmonary disorder (other than pneumonitis) 2 1 1
Disorders of eye or ear
Disturbed vision (unspeciﬁed) 4 2 5
Cataract — 1 3
Blepharitis 2 1 —
Conjunctivitis 1 — —
Scleritis — 1 —
Toxic keratitis — — 1
Ocular sarcoidosis 1 — —
Glaucoma — 1 —
Dry eyes/dry mouth — 1 —
Impaired hearing — 1 —
Other
Fever, infections 12 12 18
Rheumatoid nodulosis 4 3 2
Weight loss 4 3 —
Fatigue 3 — 2
Neuropathy 1 2 1
Vertebral fracture, osteoporosis 1 1 2
Malignancy — 2 2
Heart failure — 2 —
Sexual impotence — 1 —
Restless legs 1 — —
Total 170 212 181
*ãGT = ã-glutamyl transferase; ALAT = alanine aminotransferase.
474 van Jaarsveld,Jacobs,van der Veen,et alanalysis). Remission rates were slightly higher
in the complier analysis (27%) at two years
than in the intention to treat analysis (24%).
TOXICITY
Investigation of toxicity included three-
monthly clinical reports and laboratory abnor-
malities. All reported or observed symptoms
were included (table 6). Most patients (99%)
also took NSAIDs. Therefore, the reported
events might also have been the result of
NSAID use. In strategy I most events were
subjective gastrointestinal complaints (52), fol-
lowed by anaemia (21), and rash (17).
Mucocutaneous reactions occurred most com-
monly in strategy II (62); subjective gastroin-
testinal complaints and hepatotoxicity were
most commonly seen in strategy III, and renal
toxicity was more commonly seen in strategies
II (24) and III (17) than in strategy I (11).
These observations are in line with other pub-
lished reports.
28
Most patients reported toxicity (240, 77%):
at least one “adverse”event was reported by 76
patients (71%) in strategy I, 81 (77%) in strat-
egy III, and in 83 (82%) in strategy II. The
mean number of events for each patient was
high in strategy II: 2.1, compared with 1.6 in
strategy I and 1.7 in strategy III. Most events
were mild, not leading to any change in dose or
type of SAARD (432 of 563 events,77%).Fifty
two events led to dose adjustments of SAARD
(18 in strategy I, 17 in II, and 17 in III). A total
of 79 events led to permanent discontinuation
of an SAARD, which occurred more often in
strategy II (46 events) than in strategies I (17)
or III (16). In strategy II (46 events) the drugs
discontinued were IM gold in 30 cases,
D-penicillamine in 11 cases, and other
SAARDs in ﬁve. The drugs discontinued
permanently owing to toxicity in strategy I were
hydroxychloroquine in 10 cases and auranoﬁn
in ﬁve cases and in strategy III were methotrex-
ate in 11 and sulfasalazine in four cases, and
other SAARDs for the remaining cases.
All events were reversible, apart from four
reported malignancies (breast, skin, nasopha-
ryngeal, and oesophagus carcinoma) and one
pulmonary disorder (other than pneumonitis).
The malignancies were probably unrelated to
treatment. One case of pneumonitis occurred
in strategy II during IM gold treatment and one
in strategy III during methotrexate treatment.
A more detailed description of toxicity related
to the initial randomised drugs has been
performed.
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Discussion
In this randomised study a comparison of three
therapeutic strategies was made for patients
with recently diagnosed RA. This study is con-
sidered representative for patients with RA
referred to hospital, as all patients with recent
onset RA attending six rheumatological cen-
tres, who fulﬁlled the inclusion criteria, were
asked to participate. The study is not commu-
nity based as the population base referred to
patients with RA attending a rheumatological
centre (specialised setting). The results are
applicable to patients with early RA presenting
to a rheumatologist (that is,hospital based).To
enrol the majority of the patients and obtain an
unselected sample of patients, from whom
results are applicable to clinical practice, only a
small number of exclusion criteria were used.
Although the open label design applied in this
study might enhance bias in eVectiveness and
toxicity assessments, its protocol is closely
connected to clinical practice. Consequently,
the eVectiveness (eVects under ordinary
circumstances—that is, the pragmatic ap-
proach) rather than eYcacy (eVects under ideal
conditions) of treatment was studied.
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This study showed signiﬁcant improvements
on all primary and secondary end points
(except for radiological damage) for all three
strategies. The diVerences between the strate-
gies favoured strategies II and III rather than
strategy I; however, this was only statistically
signiﬁcant for improvement in joint score and
remission at one year. Longitudinal analysis
showed less functional disability in strategy III,
and lower ESR in strategy II than in strategy I.
In addition, radiological damage after one and
two years was signiﬁcantly lower in strategies II
and III than in strategy I. Radiological progres-
sion during the ﬁrst two years of disease was
small in all strategies,which might be the result
of the early introduction of SAARD treatment.
Consequently, the diVerences found at two
years are not of major clinical importance.
However, if linear progression proceeds at the
same rate in subsequent years, diVerences
between the strategies may become clinically
signiﬁcant.
The two-year analyses showed few statisti-
cally signiﬁcant diVerences between the strate-
gies apart from the signiﬁcantly greater radio-
logical progression in strategy I. However,
trends in the other primary end points all
favour strategies II or III. Therefore, we
conclude that eVectiveness in strategies II and
III was superior to that of strategy I. No signiﬁ-
cant diVerences were observed between strate-
gies II and III, though this study is too small to
dissociate clearly between these strategies.
Strategy II has minor disadvantages—namely,
slightly more radiological progression and tox-
icity. Strategy III comprised methotrexate with
a maximum dose of 15 mg weekly; 43% of
patients treated with methotrexate exceeded a
weekly dose of 7.5 mg and another 6%
exceeded 15 mg. Recently, higher doses are
being used, even in early RA. The eVectiveness
and toxicity of higher doses are to be evaluated.
After two years, 80% of the patients in strat-
egy III were still treated according to the
randomised strategy, which was slightly higher
than the 73% in strategy I and 70% in II.
Complier analysis showed similar results to
those of the intention to treat analysis, with
slightly better eVectiveness for strategy II, sug-
gesting that if IM gold (followed by
D-penicillamine) had not been discontinued
owing to side eVects, strategy II would have
been as eVective as strategy III or even a little
better. The higher rate of toxicity in strategy II
is an obvious disadvantage.
This study focuses on treatment strategies
rather than on speciﬁc drugs, which increases
SAARD strategies in early RA 475the number of patients continuing treatment.
The characterisation of strategy I as being mild
seems justiﬁed. EVectiveness was less than for
the other strategies and toxicity was less than in
strategy II. The characterisation of strategy II
and III as including more potent SAARDs also
seems correct in terms of eVectiveness, which
was better than that of strategy I. The toxicity
rate in strategy II was high compared with
strategy III, indicating that SAARDs used in
strategy II are more toxic than the SAARDs in
strategy III, in the prescribed dosages. As for
the characterisation of the strategies according
to the length of the lag time until treatment
eVect, it is concluded that strategy I is
associated with a long lag time and III with a
relatively short lag time. The assumption that
strategy II was also associated with a long lag
time was shown to be incorrect; similar slopes
were seen for strategies II and III. Since our
ﬁrst measurement was after three months, no
conclusions can be drawn for the preceding
months.
Although we did not compare single drugs,
we believe that the eVectiveness measured after
one year is mainly the eVect of the initial
randomised drug. This is less true at two years,
since the initial randomised SAARD was still
used by 86% after one year but by only 47%
after two years of follow up. Other studies on
the eVectiveness of SAARDs were often of
shorter duration, or included fewer patients.
Summarising these studies,moderate eVective-
ness of hydroxychloroquine and auranoﬁn has
been reported,
53 1while better eVectiveness for
other SAARDs has been found, without clear
diVerences between these SAARDs.
11 32–34 As
for radiological damage, patients treated with
IM gold, methotrexate, or sulfasalazine had a
slower progression than those treated with
hydroxychloroquine, auranoﬁn, or azathio-
prine when three diVerent trials were
compared.
20 35–37 At ﬁve years, greater progres-
sion was found for D-penicillamine than for
methotrexate.
38
SAARDs have been shown to reduce disease
activity, but remission occurs in a minority of
patients. Although the deﬁnitions of remission
diVer between studies, the reported remission
rates are concordant, and never exceed
25%.
783 94 0Remission rates of 24% after two
years for patients treated with IM gold and
12% in patients treated with methotrexate
have been reported.
84 1 In 257 patients with
early RA, followed up for four years only 15%
fulﬁlled remission criteria for at least two con-
secutive visits.
42 In our study remission rates at
one year varied from 16 to 31% and at two
years from 19 to 29%.Although these rates are
in concordance with earlier studies, we believe
that the ultimate goal in treating RA—that is,
a lasting clinical remission, is achieved in too
few cases. Other treatment options are to be
searched for to increase remission rates. Com-
bination treatment, including more than one
SAARD at the same time or new biological
agents, has not been shown to be clearly supe-
rior, but may be of interest and needs further
evaluation.
43 As this and our previous study
show, the early start of an SAARD is probably
more important than the choice of the
SAARD.
3 In addition intensive, individualised
treatment might increase treatment eVective-
ness, which might need a paradigm shift from
aiming for improvement to aiming for remis-
sion.
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